3 months ago
Spyre Therapeutics (SYRE) took a hit Wednesday after its experimental rheumatoid arthritis treatment failed to pass muster in midstage testing.
But **** ysts are far more interested in Spyre's inflammatory bowel disease drugs. These conditions include ulcerative colitis and Crohn's disease.
"Even excluding all non-UC (ulcerative colitis) indications, our PT (price target) would remain at ~$115, well above current trading levels," Wedbush **** yst David Nierengarten said in a client note. "While we view the RS (rheumatoid arthritis) results as disappointing, we see limited impact to our core IBD-driven (inflammatory bowel disease) thesis."
Still, Spyre stock fell 1.8%, closing at 93.61. Shares are highly rated with a strong IBD Digital Relative Strength Rating of 98, putting the stock's 12-month performance in the leading 2% of all stocks.
Spyre's drug, dubbed SPY072, actually showed some effectiveness in patients with rheumatoid arthritis. But the results didn't pass the company's internal bar for advancement. Spyre is still testing SPY072 in other rheumatology indications, including psoriatic arthritis and axial spondyloarthritis.
#arthritis #testing #bowel
But **** ysts are far more interested in Spyre's inflammatory bowel disease drugs. These conditions include ulcerative colitis and Crohn's disease.
"Even excluding all non-UC (ulcerative colitis) indications, our PT (price target) would remain at ~$115, well above current trading levels," Wedbush **** yst David Nierengarten said in a client note. "While we view the RS (rheumatoid arthritis) results as disappointing, we see limited impact to our core IBD-driven (inflammatory bowel disease) thesis."
Still, Spyre stock fell 1.8%, closing at 93.61. Shares are highly rated with a strong IBD Digital Relative Strength Rating of 98, putting the stock's 12-month performance in the leading 2% of all stocks.
Spyre's drug, dubbed SPY072, actually showed some effectiveness in patients with rheumatoid arthritis. But the results didn't pass the company's internal bar for advancement. Spyre is still testing SPY072 in other rheumatology indications, including psoriatic arthritis and axial spondyloarthritis.
#arthritis #testing #bowel
3 months ago
Spyre Therapeutics (SYRE) has surged more than 565% over the past year, driven by strong technical momentum.
Shares are trading at a new 3-year high.
SYRE maintains a 100% "Buy" technical opinion from Barchart.
Short interest is elevated at 13.81% of float, highlighting volatility and the need for disciplined risk management.
Valued at $9.5 billion, Spyre Therapeutics (SYRE) is a biotechnology company which aims to create inflammatory bowel disease products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection.
#year #short
Shares are trading at a new 3-year high.
SYRE maintains a 100% "Buy" technical opinion from Barchart.
Short interest is elevated at 13.81% of float, highlighting volatility and the need for disciplined risk management.
Valued at $9.5 billion, Spyre Therapeutics (SYRE) is a biotechnology company which aims to create inflammatory bowel disease products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection.
#year #short
3 months ago
Spyre Therapeutics (SYRE) has surged more than 565% over the past year, driven by strong technical momentum.
Shares are trading at a new 3-year high.
SYRE maintains a 100% "Buy" technical opinion from Barchart.
Short interest is elevated at 13.81% of float, highlighting volatility and the need for disciplined risk management.
Valued at $9.5 billion, Spyre Therapeutics (SYRE) is a biotechnology company which aims to create inflammatory bowel disease products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection.
#syre #technical #short #valued
Shares are trading at a new 3-year high.
SYRE maintains a 100% "Buy" technical opinion from Barchart.
Short interest is elevated at 13.81% of float, highlighting volatility and the need for disciplined risk management.
Valued at $9.5 billion, Spyre Therapeutics (SYRE) is a biotechnology company which aims to create inflammatory bowel disease products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection.
#syre #technical #short #valued
